

# SAFETY DATA SHEET

## 1. Identification

Product identifier	Lidocaine Hydrochloride Topical Solution USP 4%
Other means of identification	None.
Recommended use	Indicated for the production of topical anesthesia
<b>Recommended restrictions</b>	None known.
Manufacturer/Importer/Supplier/	Distributor information
Company name Address	Boehringer Ingelheim Roxane Inc. 1809 Wilson Road Columbus, Ohio 43228
Telephone	(614) 276-4000
Emergency phone number	(614) 276-4000
2. Hazard(s) identification	
Physical hazards	Not classified.
Health hazards	Not classified.
OSHA defined hazards	Not classified.
Label elements	
Hazard symbol	None.
Signal word	Warning
Hazard statement	This is a pharmaceutical product designed to be prescribed by a licensed health care professional. Should any person while using this product observe any adverse health effects, they should seek medical treatment.
Precautionary statement	
Prevention	Observe good industrial hygiene practices.
Response	Wash hands after handling.
Storage	Store away from incompatible materials. Keep from freezing. Store at a controlled room temperature, 20°- 25° C (68°-77° F.)
Disposal	Incineration of waste at an approved USEPA incinerator is recommended.
Hazard(s) not otherwise classified (HNOC)	None known.

# 3. Composition/information on ingredients

#### Substances

Chemical name	Common name and synonyms	CAS number	%
2 - (diethylamino)-N-(2,6-dimethyl phenyl)-acetamide		73-78-9	4%
Composition comments	Components not listed are either non-hazardous or are below reportable limits. Refer to Physician's Desk Reference for common components present at <1%		
4. First-aid measures			
Inhalation	Move to fresh air. Call a physician if symptom	ns develop or persist.	
Skin contact	Wash off with soap and water. Get medical attention if irritation develops and persists.		
Eye contact	Rinse with water. Get medical attention if irritation develops and persists.		
Ingestion	Rinse mouth. Get medical attention if sympto call a poison control center immediately.	ms occur. If ingestion of a lar	ge amount does occur

Most important symptoms/effects, acute and delayed

Indication of immediate medical attention and special treatment needed General information drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. Allergic reactions as a result of sensitivity to lidocaine are extremely rare. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

Side effects may include: CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness,

Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

## 5. Fire-fighting measures

Suitable extinguishing media	Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).
Unsuitable extinguishing media	Do not use water jet as an extinguisher, as this will spread the fire.
Specific hazards arising from the chemical	During fire, gases hazardous to health may be formed.
Special protective equipment and precautions for firefighters	Self-contained breathing apparatus and full protective clothing must be worn in case of fire.
Fire fighting equipment/instructions	Use water spray to cool unopened containers.
Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.
General fire hazards	No unusual fire or explosion hazards noted.

### 6. Accidental release measures

Personal precautions,Keeprotective equipment and8).emergency procedures	
containment and cleaning up was	e up with absorbent material. Following product recovery, flush area with water. Incineration of te at an approved USEPA incinerator is recommended. id discharge into drains, water courses or onto the ground.

### 7. Handling and storage

Precautions for safe handling	Avoid contact with eyes, skin, and clothing. Wash hands thoroughly after handling.
Conditions for safe storage, including any incompatibilities	Store away from incompatible materials (see Section 10 of the SDS). Do not freeze. Store at controlled room temperature at $20-25$ °C (68-77°F).

### 8. Exposure controls/personal protection

Occupational exposure limits Biological limit values Appropriate engineering controls	No exposure limits noted for ingredient(s). No biological exposure limits noted for the ingredient(s). Ventilation should be matched to conditions.
Individual protection measures,	such as personal protective equipment
Eye/face protection	Avoid contact with eyes. In laboratory, medical or industrial settings, safety glasses with side shields are recommended. The use of goggles or full face protection may be required depending on the industrial exposure setting.
Skin protection	
Hand protection	Wear protective gloves (i.e. latex, nitrile, neoprene). Wash hands after contact.
Other	Wash promptly with soap and water if skin becomes contaminated. In laboratory, medical or industrial settings, gloves and lab coats are recommended. The use of additional personal protective equipment such as shoe coverings, gauntlets, hood or head coverings may be necessary.
<b>Respiratory protection</b>	None required for consumer use.
Thermal hazards	Wear appropriate thermal protective clothing, when necessary.
General hygiene considerations	Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

### 9. Physical and chemical properties

# 10. Stability and reactivity

Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	Contact with incompatible materials. Keep from freezing.
Incompatible materials	Strong oxidizing agents.
Hazardous decomposition products	No hazardous decomposition products are known.

# 11. Toxicological information

### Information on likely routes of exposure

Inhalation	Not expected to be hazardous in final pharmaceutical form.
Skin contact	Contact will cause localized anesthesia.
Eye contact	Contact will cause localized anesthesia. Direct contact with eyes may cause temporary irritation.
Ingestion	Do not ingest.
Symptoms related to the physical, chemical and toxicological characteristics	Side effects may include: CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. Allergic reactions as a result of sensitivity to lidocaine are extremely rare.

#### Information on toxicological effects

Acute toxicity	May be harmful if swallowed in l	arge quantities.		
Components	Species	Test Results		
2 - (diethylamino)-N-(2,6-dimethy	(Iphenyl)-acetamide (CAS 73-78-9)			
Acute				
Oral		"		
	Mouse	220 mg/kg		
Skin corrosion/irritation	Contact will cause localized ane	sthesia.		
Serious eye damage/eye irritation	Contact will cause localized anesthesia. Direct contact with eyes may cause temporary irritation.			
Respiratory or skin sensitization	on			
Respiratory sensitization	Not a respiratory sensitizer.			
Skin sensitization	This product is not expected to cause skin sensitization.			
Germ cell mutagenicity		No mutagenicity studies have been conducted		
Carcinogenicity	Long-term studies in animals have not been conducted to evaluate carcinogenic potential			
OSHA Specifically Regulat Not listed.	ed Substances (29 CFR 1910.100	1-1050)		
Reproductive toxicity	Pregnancy Category B			
		controlled studies in pregnant women. Because animal ays predictive of human response, this drug should be used during I.		
		luct is excreted in human milk. Because many drugs are excreted exercised when administering to a nursing woman		
Specific target organ toxicity - single exposure	Not classified.			
Specific target organ toxicity - repeated exposure	Not classified.			
Aspiration hazard	Not classified.			
Further information	See package insert.			
12. Ecological informatio	n			
Ecotoxicity	The product is not classified as	environmentally hazardous.		
Persistence and degradability	No data is available on the degra	adability of this product.		
Bioaccumulative potential	No data available.			
Mobility in soil	No data available.			
Other adverse effects	None.	None.		
13. Disposal consideration	ons			
Disposal instructions	Collect and reclaim or dispose ir	n sealed containers at licensed waste disposal site.		
Local disposal regulations	Dispose in accordance with all a	pplicable regulations.		
Hazardous waste code	The waste code should be assig disposal company.	ned in discussion between the user, the producer and the waste		

Waste from residues / unused Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: products Disposal instructions). Empty containers should be taken to an approved waste handling site for recycling or disposal.

**Contaminated packaging** Since emptied containers may retain product residue, follow label warnings even after container is

# 14. Transport information

#### DOT

Not regulated as dangerous goods.

#### ΙΑΤΑ

Not regulated as dangerous goods.

emptied.

#### IMDG

Not regulated as dangerous goods.

# Transport in bulk according to Not available. Annex II of MARPOL 73/78 and the IBC Code

#### 15. Regulatory information

```
US federal regulations
```

This material is not listed on the US TSCA 8(b) Inventory, therefore it may only be used for TSCA exempt purposes such as R&D or drug use. Over-the-counter drugs in their solid final form (i.e. tablets or pills) are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 29 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limits may be surpassed, they can be considered hazardous.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)				
Not regulated.				
OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)				
Not listed.	Not listed.			
CERCLA Hazardous Substan	nce List (40 CFR 302.4)			
Not listed.				
Superfund Amendments and Reauthorization Act of 1986 (SARA)				
Hazard categories	Immediate Hazard - No Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No			
SARA 302 Extremely hazardous substance				
Not listed.				
SARA 311/312 Hazardous chemical	No			
SARA 313 (TRI reporting) Not regulated.				
Other federal regulations				
Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List				
	112(r) Accidental Release Prevention (40 CFR 68.130)			
Not regulated.	N			
Safe Drinking Water Act (SDWA)	Not regulated.			
US state regulations				
US. Massachusetts RTK - Su	bstance List			
Not regulated.				
-	Community Right-to-Know Act			
Not listed.	d Community Right to Know Low			
Not listed.	US. Pennsylvania Worker and Community Right-to-Know Law			
US: Rhode Island RTK				
Not regulated.				
US. California Proposition 65 Not Listed.				
International Inventories				
	Inventory name			
Country(s) or region Australia	Inventory name Australian Inventory of Chemical Substances (AICS)			
Canada	Domestic Substances List (DSL)			
Canada	Non-Domestic Substances List (DSL)			
China				
Unina	Inventory of Existing Chemical Substances in China (IECSC)			

Yes Yes No Yes

On inventory (yes/no)\*

Country(s) or region	Inventory name	On inventory (yes/no)*
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	Yes
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	Yes
Korea	Existing Chemicals List (ECL)	Yes
New Zealand	New Zealand Inventory	Yes
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	Yes
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	Yes

\*A "Yes" indicates this product complies with the inventory requirements administered by the governing country(s). A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

# 16. Other information, including date of preparation or last revision

Issue date	20-March-2015
Revision date	-
Version #	01
References	1) Lidocaine Hydrochloride Topical Solution USP 4%, Package Insert, Roxane Laboratories, Inc., Columbus, Ohio
	2) PDR – Physicians Desk Reference.
	3) Ariel Webinsight. Regulatory and ChemExpert Database.
Disclaimer	Boehringer Ingelheim Roxane Inc. cannot anticipate all conditions under which this information and its product, or the products of other manufacturers in combination with its product, may be used. It is the user's responsibility to ensure safe conditions for handling, storage and disposal of the product, and to assume liability for loss, injury, damage or expense due to improper use. The information in the sheet was written based on the best knowledge and experience currently available.